sunitinib viatris 50 mg capsule rigide
viatris pharma gmbh - sunitinibum - capsule rigide - sunitinibum 50 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium, povidonum, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - farmaco - synthetika
posaconazol viatris 40 mg/ml sospensione orale
viatris pharma gmbh - posaconazolum - sospensione orale - posaconazolum 200 mg, acidum citricum monohydricum, natrii dihydrogenocitras anhydricus, natrii benzoas 10 mg, natrii laurilsulfas, simeticonum, methylcellulosum, acidum sorbicum, xanthani gummi, glycerolum, glucosum liquidum 2108.5 mg, e 171, aromatica (kirschen), aqua purificata ad suspensionem pro 5 ml corresp. natrium 5.91 mg. - infezioni fungine - synthetika
posaconazol viatris 100 mg compressa gastroresistente
viatris pharma gmbh - posaconazolum - compressa gastroresistente - posaconazolum 100 mg, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, triethylis citras, xylitolum, hydroxypropylcellulosum, e 310, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum, natrii stearylis fumaras, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (flavum), pro compresso obducto corresp. natrium 2.4 mg. - infezioni fungine - synthetika
abirateron viatris 500 mg compresse rivestite con film
viatris pharma gmbh - abirateroni acetas - compresse rivestite con film - abirateroni acetas 500 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 30, cellulosum microcristallinum, lactosum monohydricum 68.0 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (rubrum), e 172 (nigrum), pro compresso obducto corresp. natrium 10.21 mg. - prostatico - synthetika
abirateron viatris 1000 mg compresse rivestite con film
viatris pharma gmbh - abirateroni acetas - compresse rivestite con film - abirateroni acetas 1000 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 30, cellulosum microcristallinum, lactosum monohydricum 136.0 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, pro compresso obducto corresp. natrium 20.41 mg. - prostatico - synthetika
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agenti antitrombotici - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
letrozol viatris compresse rivestite con film
viatris pharma gmbh - letrozolum - compresse rivestite con film - letrozolum 2.5 mg, lactosum monohydricum 61.5 mg, cellulosum microcristallinum, amylum pregelificatum, carboxymethylamylum natricum a corresp. natrium 0.14-0.21 mg, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (flavum) pro compresso obducto. - cytostatikum - synthetika
latanoprost viatris collirio
viatris pharma gmbh - latanoprostum - collirio - latanoprostum 50 µg, natrii chloridum, natrii dihydrogenophosphas monohydricus et dinatrii phosphas corresp. phosphas 6.34 mg, aqua ad iniectabile, benzalkonii chloridum 0.2 mg, ad solutionem pro 1 ml. - il glaucoma - synthetika
co-latanoprost viatris collirio
viatris pharma gmbh - latanoprostum, timololum - collirio - latanoprostum 50 µg, timololum 5 mg ut timololi maleas, dinatrii phosphas et natrii dihydrogenophosphas monohydricus corresp. phosphas 6.33 mg, natrii chloridum, acidum hydrochloridum aut natrii hydroxidum ad ph, benzalkonii chloridum 0.2 mg, aqua ad iniectabile, ad solutionem pro 1 ml. - stretto, okuläre ipertensione - synthetika
tenofovir viatris 245 mg compresse rivestite con film
viatris pharma gmbh - tenofovirum disoproxilum - compresse rivestite con film - tenofovirum disoproxilum 245 mg ut tenofoviri disoproxili maleas, cellulosum microcristallinum, lactosum monohydricum 150 mg, hydroxypropylcellulosum substitutum humile, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 5.04 mg, triacetinum, e 171, e 132, pro compresso obducto. - hiv-infektion, epatite b - synthetika